Longeveron (LGVN) Research & Development (2020 - 2026)
Longeveron's (LGVN) quarterly Research & Development came in at $2.3 million in Q1 2026, down 7.79% year-on-year from $2.5 million in Q1 2025, and down 14.74% quarter-over-quarter from $2.7 million in Q4 2025.
Longeveron (LGVN) Research & Development (2020 - 2026) Analysis & Trends
Longeveron's Research & Development history runs 7 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- On a quarterly basis, Research & Development fell 7.79% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $11.8 million, a 40.48% increase from a year earlier, with the FY2025 full-year figure at $12.0 million, up 47.98% from the prior year.
- Research & Development slipped to $2.3 million in Q1 2026 per LGVN's latest filing, from $2.7 million in the prior quarter.
- Across five years, Research & Development topped out at $3.9 million in Q3 2025 and bottomed at $234000.0 in Q2 2022.
- The 5-year median for Research & Development is $2.2 million (2024), against an average of $2.2 million.
- Across the five-year window, Research & Development soared 880.0% in 2022 and tumbled 33.93% in 2023, its largest moves.
- Year by year, Research & Development stood at $3.3 million in 2022, then plunged by 33.93% to $2.2 million in 2023, then declined by 7.75% to $2.0 million in 2024, then soared by 36.75% to $2.7 million in 2025, then fell by 14.74% to $2.3 million in 2026.
- Per Business Quant, the three latest LGVN Research & Development figures stand at $2.3 million (Q1 2026), $2.7 million (Q4 2025), and $3.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.32 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 2.95 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 2.21 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | 2.16 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 3.26 Mn |
| Sep 30, 2022 | 245,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Mar 31, 2022 | 1.29 Mn |
| Dec 31, 2021 | -4.15 Mn |
| Sep 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 53,000.00 |